ObjectiveTo observe the clinical efficacy of erythropoietin and iron saccharate on patients with cancerous anemia. MethodsA total of 300 cases with cancerous anemia admitted to our hospital from June 2015 to June 2018 were selected and randomly divided into three groups, erythropoietin group (treated with erythropoietin), iron saccharate group (treated with iron saccharate) and combination treatment group (treated with erythropoietin combined with iron saccharate), with 100 cases in each group. Three groups were treated continuously for 8 weeks. The clinical therapeutic effect, life quality score (KPS score), red blood cell (RBC) count, hemoglobin (HGB) and hematocrit (HCT) levels of the three groups were compared. ResultsThe total effective rates of erythropoietin group, iron saccharate group and combination treatment group were 87.0%, 75.0% and 97.0%, respectively. The total effective rates were statistically significantly different among the three groups (P＜0.05).After 8 weeks of treatment, the KPS score, RBC, HGB and HCT were significantly increased in the three groups, and the ascending order were iron saccharate group, erythropoietin group and combination treatment group, the difference was statistically significant (P＜0.05). ConclusionErythropoietin combined with iron saccharate have definite curative effects on cancerous anemia, which can significantly improve the RBC, HGB, HCT levels and the life quality, and its effect is obviously superior to that of separate treatment.

无